Continuous-flow 3D glass substrate device safely captures circulating tumor cells, demonstrating potential to reduce metastasis and improve cancer survival.

Combined ctDNA and PD-L1–positive CTC analysis improves monitoring of metastasis, minimal residual disease, and treatment response in lung cancer.

This multi-cancer study shows CTC and PD-L1 prevalence across Indian patients, supporting minimal residual disease monitoring and personalized cancer care.

Study shows circulating tumor cells with PD-L1 expression and clusters in sarcoma, indicating minimal residual disease and need for long-term monitoring.

A set of 17 co-occurring TSG mutations has been identified as key biomarkers for early relapse in mEGFR
lung adenocarcinoma. Longitudinal genomic monitoring, with a focus on clonal evolution, offers valuable insights that can inform personalized treatment strategies and potentially improve patient outcomes.

Study links radiotherapy exposure with circulating tumor cells and PD-L1 expression, indicating possible minimal residual disease and metastatic risk.

Integrated ctDNA and CTC analysis correlates with PET-CT outcomes to reveal treatment resistance and aggressive cancer progression.

CTC detection with PD-L1 overexpression reveals aggressive pancreatic cancer and potential biomarker value for monitoring metastasis and disease progression.

Single CTC genomics reveals actionable mutations and therapy resistance signatures not detected in paired ctDNA in advanced colorectal cancer.

Inverse 3D lab-on-chip microfilms for selective CTC capture from blood.

Nirmal Raut, Atul Bharde, Sreeja Jayant, Gaurishankar Aland, Aravindan Vasudevan, Jayant Khandare

CTC detection with PD-L1 expression reveals residual disease despite negative radiological findings in treated cancer patients.

CTCs with PD-L1 expression in ovarian cancer reveal minimal residual disease and may guide immunotherapy and early metastasis monitoring.

CTC detection with PD-L1 expression in colorectal cancer reveals minimal residual disease and supports personalized treatment strategies.

Dual biomarker analysis of ctDNA and circulating tumor cells reveals disease progression and metastasis across multiple cancer types.

Complementary ctDNA and CTC biomarkers reveal minimal residual disease and predict cancer progression after curative-intent treatment.

Large-scale analysis of circulating tumor cells and clusters reveals their role in predicting aggressive epithelial cancers and treatment resistance.

HER2 analysis on circulating tumor cells using the OncoDiscover® platform enables real-time, non-invasive profiling for improved metastatic breast cancer treatment decisions.

Study links Shh/Nrf2 overexpression with circulating tumor cells in HNSCC, highlighting their potential as biomarkers for early detection and survival prediction.

CTC analysis using OncoDiscover® enables dynamic detection of PD-L1 and EGFR targets in advanced lung cancer, supporting personalized targeted and immunotherapy decisions.